Review article: Biliary and hepatic involvement in IgG4-related disease

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 11-12, 2014, Pages 1251-1261

  Joshi, D ^a   Webster, G J M ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOGLOBULIN G4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; IMMUNOGLOBULIN G;

AGE DISTRIBUTION; AUTOIMMUNE PANCREATITIS; BILE DUCT CARCINOMA; CHOLANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HISTOLOGY; HUMAN; IMAGING; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN G4 RELATED DISEASE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INCIDENCE; LIVER CANCER; LOW DRUG DOSE; PANCREAS CARCINOMA; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; RELAPSE; REVIEW; SCLEROSING CHOLANGITIS; SINGLE DRUG DOSE; STEROID THERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION; ULTRASOUND; AUTOIMMUNE DISEASES; BLOOD; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; LIVER DISEASES; PANCREATIC NEOPLASMS; PANCREATITIS; PATHOPHYSIOLOGY;

AUTOIMMUNE DISEASES; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOGLOBULIN G; LIVER DISEASES; PANCREATIC NEOPLASMS; PANCREATITIS; STEROIDS;

EID: 84909645899     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12988     Document Type: Review

References (63)

1. Kamisawa T, Egawa N, Nakajima H. Autoimmune pancreatitis is a systemic autoimmune disease. Am J Gastroenterol 2003; 98: 2811-2.
2. Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003; 38: 982-4.
3. Sah RP, Chari ST, Pannala R, et al. Differences in clinical profi le and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology 2010; 139: 140-8; quiz e12-3.
4. Okazaki K, Uchida K, Koyabu M, Miyoshi H, Takaoka M. Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease. J Gastroenterol 2011; 46: 277-88.
5. Dahlgren M, Khosroshahi A, Nielsen GP, Deshpande V, Stone JH. Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res 2010; 62: 1312-8.
6. Saeki T, Saito A, Hiura T, et al. Lymphoplasmacytic infiltration of multiple organs with immunoreactivity for IgG4: IgG4-related systemic disease. Intern Med 2006; 45: 163-7.
7. Kamisawa T, Takuma K, Egawa N, Tsuruta K, Sasaki T. Autoimmune pancreatitis and IgG4-related sclerosing disease. Nat Rev Gastroenterol Hepatol 2010; 7: 401-9.
8. Stone JH, Khosroshahi A, Hilgenberg A, Spooner A, Isselbacher EM, Stone JR. IgG4-related systemic disease and lymphoplasmacytic aortitis. Arthritis Rheum 2009; 60: 3139-45.
9. Hamano H, Arakura N, Muraki T, Ozaki Y, Kiyosawa K, Kawa S. Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis. J Gastroenterol 2006; 41: 1197-205.
10. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011; 40: 352-8.
11. Kalaitzakis E, Webster GJ. Review article: autoimmune pancreatitis - management of an emerging disease. Aliment Pharmacol Ther 2011; 33: 291-303.
12. Cheuk W, Chan JK. IgG4-related sclerosing disease: a critical appraisal of an evolving clinicopathologic entity. Adv Anat Pathol 2010; 17: 303-32.
13. Kawa S, Ota M, Yoshizawa K, et al. HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology 2002; 122: 1264-9.
14. Park do H, Kim MH, Oh HB, et al. Substitution of aspartic acid at position 57 of the DQbeta1 affects relapse of autoimmune pancreatitis. Gastroenterology 2008; 134:440-6.
15. Frulloni L, Lunardi C, Simone R, et al. Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med 2009; 361: 2135-42.
16. Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008; 14: 337-42.
17. Zen Y, Fujii T, Harada K, et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 2007; 45: 1538-46.
18. van der Zee JS, van Swieten P, Aalberse RC. Inhibition of complement activation by IgG4 antibodies. Clin Exp Immunol 1986; 64: 415-22.
19. Kountouras J, Zavos C, Chatzopoulos D. A concept on the role of Helicobacter pylori infection in autoimmune pancreatitis. J Cell Mol Med 2005; 9: 196-207.
20. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39: 469-77.
21. Deshpande V, Chicano S, Finkelberg D, et al. Autoimmune pancreatitis: a systemic immune complex mediated disease. Am J Surg Pathol 2006; 30: 1537-45.
22. Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101: 2070-5.
23. Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol 2010; 34: 1812-9.
24. Kanno A, Nishimori I, Masamune A, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan. Pancreas 2012; 41 : 835-9.
25. Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol 2006; 4: 1010-6; quiz 934.
26. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012; 25: 1181-92.
27. Khosroshahi A, Stone JH. Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol 2011; 23: 67-71.
28. Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine 2012; 91: 57-66.
29. Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62: 1755-62.
30. Shiokawa M, Kodama Y, Yoshimura K, et al. Risk of cancer in patients with autoimmune pancreatitis. Am J Gastroenterol 2013; 108: 610-7.
31. Huggett M. Type 1 AIP and IgG4-related sclerosing cholangitis is associated with extra-pancreatic organ failure, malignancy and mortality in a prospective UK cohort. Am J Gastroenterol 2014; doi:10.1038/ajg.2014.223.
32. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134: 706-15.
33. Hirano K, Shiratori Y, Komatsu Y, et al. Involvement of the biliary system in autoimmune pancreatitis: a follow-up study. Clin Gastroenterol Hepatol 2003; 1: 453-64.
34. Church NI, Pereira SP, Churchill D, Cairns S, Hatfield AR, Webster GJ. Chronic pancreatitis: diagnosis and management of complications. Gut 2007; 56: 1189-90.
35. Nishino T, Toki F, Oyama H, et al. Biliary tract involvement in autoimmune pancreatitis. Pancreas 2005; 30: 76-82.
36. Yang DH, Kim KW, Kim TK, et al. Autoimmune pancreatitis: radiologic findings in 20 patients. Abdom Imaging 2006; 31: 94-102.
37. Sahani DV, Kalva SP, Farrell J, et al. Autoimmune pancreatitis: imaging features. Radiology 2004; 233: 345-52.
38. Nakazawa T, Naitoh I, Hayashi K, Miyabe K, Simizu S, Joh T. Diagnosis of IgG4-related sclerosing cholangitis. World J Gastroenterol 2013; 19: 7661-70.
39. Sugumar A, Levy MJ, Kamisawa T, et al. Endoscopic retrograde pancreatography criteria to diagnose autoimmune pancreatitis: an international multicentre study. Gut 2011; 60: 666-70.
40. Hyodo N, Hyodo T. Ultrasonographic evaluation in patients with autoimmune-related pancreatitis. J Gastroenterol 2003; 38: 1155-61.
41. Sah RP, Chari ST. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Curr Opin Rheumatol 2011; 23: 108-13.
42. Ghazale A, Chari ST, Smyrk TC, et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007; 102: 1646-53.
43. Nakazawa T, Naitoh I, Hayashi K, et al. Diagnostic criteria for IgG4-related sclerosing cholangitis based on cholangiographic classification. J Gastroenterol 2012; 47: 79-87.
44. Ohara H, Nakazawa T, Kawa S, et al. Establishment of a serum IgG4 cut-off value for the differential diagnosis of IgG4-related sclerosing cholangitis: a Japanese cohort. J Gastroenterol Hepatol 2013; 28: 1247-51.
45. Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/ immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol 2009; 7: 1089-96.
46. Moon SH, Kim MH, Park do H, et al. IgG4 immunostaining of duodenal papillary biopsy specimens may be useful for supporting a diagnosis of autoimmune pancreatitis. Gastrointest Endosc 2010; 71: 960-6.
47. Kubota K, Iida H, Fujisawa T, et al. Clinical signi ficance of swollen duodenal papilla in autoimmune pancreatitis. Pancreas 2007; 35: e51-60.
48. Kim MH, Moon SH, Kamisawa T. Major duodenal papilla in autoimmune pancreatitis. Dig Surg 2010; 27: 110-4.
49. Hirano K, Fukushima N, Tada M, et al. Diagnostic utility of biopsy specimens for autoimmune pancreatitis. J Gastroenterol 2009; 44: 765-73.
50. Okano N, Igarashi Y, Kishimoto Y, Ito K, Sasai D. Case of immunoglobulin G4-related cholangitis accompanying autoimmune pancreatitis: diagnosis by peroral cholangioscopy and treatment by endoscopic biliary stenting. Dig Endosc 2012; 24(Suppl. 1): 62-6.
51. Itoi T, Kamisawa T, Igarashi Y, et al. The role of peroral video cholangioscopy in patients with IgG4-related sclerosing cholangitis. J Gastroenterol 2013; 48: 504-14.
52. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-78.
53. Nakazawa T, Ohara H, Sano H, et al. Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitis. Pancreas 2005; 30: 20-5.
54. Nishino T, Oyama H, Hashimoto E, et al. Clinicopathological differentiation between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis. J Gastroenterol 2007; 42: 550-9.
55. Kalaitzakis E, Levy M, Kamisawa T, et al. Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma. Clin Gastroenterol Hepatol 2011; 9: 800-3.
56. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504-7.
57. Bjornsson E, Chari S, Silveira M, et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther 2011; 18: 198-205.
58. Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut 2013; 62: 1607-15.
59. Zen Y, Fujii T, Sato Y, Masuda S, Nakanuma Y. Pathological classification of hepatic inflammatory pseudotumor with respect to IgG4-related disease. Mod Pathol 2007; 20: 884-94.
60. Chung H, Watanabe T, Kudo M, Maenishi O, Wakatsuki Y, Chiba T. Identification and characterization of IgG4-associated autoimmune hepatitis. Liver Int 2010; 30: 222-31.
61. Umemura T, Zen Y, Hamano H, Kawa S, Nakanuma Y, Kiyosawa K. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology 2007; 46: 463-71.
62. Rituximab in IgG4-related disease: a phase 1-2 trial. Available at: http://www.clinicaltrials.gov. NCT01584388 (accessed March 2014).
63. Glucocorticoids in patients with IgG4-RD. Available at: http://www.clinicaltrials.gov (accessed March 2014). NCT01758393.